Skip to content
10-Q

Quarterly Report

STANDARD BIOTOOLS INC. LAB

0001193125-26-208967

← back to feed
Filed
May 6, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 388.2M sh
Shares Diluted Q1 2026 · Mar 31, 2025 378.23M sh
Capex Q1 2026 · Mar 31, 2026 $570K
Capex Q1 2026 · Mar 31, 2025 $5.05M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$46.6M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$30.28M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $265.77M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $120.86M
Stockholders Equity Q1 2026 · Mar 31, 2026 $561.12M
Stockholders Equity Q1 2026 · Dec 31, 2025 $424.29M
Stockholders Equity Q1 2026 · Mar 31, 2025 $454.6M
Stockholders Equity Q1 2026 · Dec 31, 2024 $471.72M
Current Liabilities Q1 2026 · Mar 31, 2026 $42.2M
Current Liabilities Q1 2026 · Dec 31, 2025 $108.31M
Total Liabilities Q1 2026 · Mar 31, 2026 $77.99M
Total Liabilities Q1 2026 · Dec 31, 2025 $143.46M
Current Assets Q1 2026 · Mar 31, 2026 $521.45M
Current Assets Q1 2026 · Dec 31, 2025 $454.26M
Total Assets Q1 2026 · Mar 31, 2026 $639.11M
Total Assets Q1 2026 · Dec 31, 2025 $567.75M
Eps Diluted Q1 2026 · Mar 31, 2026 $0.33
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.07
Eps Basic Q1 2026 · Mar 31, 2026 $0.33
Eps Basic Q1 2026 · Mar 31, 2025 −$0.07
Sga Expense Q1 2026 · Mar 31, 2026 $18.61M
Sga Expense restated Q1 2026 · Mar 31, 2025 $29.82M
Rd Expense Q1 2026 · Mar 31, 2026 $2.12M
Rd Expense restated Q1 2026 · Mar 31, 2025 $5.44M
Net Income Q1 2026 · Mar 31, 2026 $127.07M
Net Income Q1 2026 · Mar 31, 2025 −$26.03M
Operating Income Q1 2026 · Mar 31, 2026 −$12.5M
Operating Income restated Q1 2026 · Mar 31, 2025 −$26.97M
Gross Profit Q1 2026 · Mar 31, 2026 $11.31M
Gross Profit restated Q1 2026 · Mar 31, 2025 $11.05M
Revenue Q1 2026 · Mar 31, 2026 $21.15M
Revenue restated Q1 2026 · Mar 31, 2025 $20.22M